Patients & family

Glycostem Therapeutics is focused on the development of stem cell-derived Natural Killer cells (NK cells) as a medicinal asset in the fight against cancer. NK cells are the new star in the domain of cellular immunotherapy, due to their tightly regulated “natural killing” of cancer cells; they play an important role in control and even cure of both solid and hematological malignancies, like Acute Myeloid Leukemia (AML) and Multiple Myeloma (MM).

Glycostem’s commitment to the patient community is not limited to NK cell therapies development, but encompasses a better understanding of the needs and experiences of patients with cancer and their families.

Better response of the immune system

Glycostem is focused on developing first and next generation cancer therapeutics based on NK cells. When the cells of a patient’s immune system are not strong enough to fight cancer cells, the infusion of NK cells collected from a donor may contribute to a better response by the patient's immune system. Thus, venous infusion of a large number of NK cells could contribute to the body's fight against cancer cells.

Checking NK Cells HR

Our solution

oNKord®  is a frozen off-the-shelf investigational cell therapy product for venous infusion which contain a large number of NK cells. oNKord® is expanded and activated ex vivo for the treatment of patients with hematologic malignancies like acute myeloid leukemia or multiple myeloma and also for the treatment of patients with solid tumors.

oNKord® is produced in our state-of-the art R&D facilities, located in Oss, the Netherlands. Our highly qualified staff ensures our solutions meet the highest scientific, operational and quality standards possible. They collaborate every day towards the shared ambition of curing cancer.

Clinical trials

oNKord® is available only for patients enrolled in clinical trials. A clinical study completed in the Netherlands in 2015 demonstrated a good safety profile for single infusion and promising efficacy signal in 10 elderly and frail patients with acute myeloid leukemia (AML) not eligible for hematopoietic stem cell transplantation.

Clinical development of oNKord® in hematologic malignancies with repeat infusion 4 days apart started in 2020, based on the recommended phase II dose. Glycostem’s manufacturing facilities have been granted license to produce NK cells for clinical trials by the competent authority in the Netherlands. For information about ongoing clinical trials of our investigational therapies, please view our pipeline.

patient and family

Collaborating partners

A growing number of commercial and academic partners have chosen Glycostem because of our expertise with NK cells and their production. We build bridges between the commercial and scientific parts of our companies and maintain close relationships with our partners.